2020 American Transplant Congress
Evaluation of the Safety and Efficacy of Valganciclovir to Prevent Cytomegalovirus Infection in Pediatric Solid Organ Transplant Recipients Utilizing Two Dosing Regimens
Pharmacy, Ann and Robert H. Lurie Children's Hospital, Chicago, IL
*Purpose: Valganciclovir (VGCV) is FDA-approved for CMV prophylaxis in children aged one month to sixteen years old using the Pescovitz algorithm (7 x body surface…2020 American Transplant Congress
The Value of Pharmacist-Driven Valganciclovir Dosing in Kidney Transplant Recipients in Reducing CMV Infection: A Single Center Experience
*Purpose: Cytomegalovirus (CMV) is a common viral infection after kidney transplant (KT) despite prophylaxis with valganciclovir (VGCV). VGCV is renally dosed and can be a…2020 American Transplant Congress
CMV, EBV and BKV Viremia Rate Varied Depending on the Timing of Conversion to Belatacept (BLT)- from Calcineurin Inhibitor (CNI)-Based Immunosuppression and HLA-Sensitization (HS) Status in Kidney Transplant Patients (KTx Pts)
Cedars-Sinai Medical Center, Los Angeles, CA
*Purpose: Viral infections (VI) represent significant morbidity and mortality factors for KTx Pts. We previously showed more VI in BLT-treated Pts compared with CNI Pts…2020 American Transplant Congress
Reduced Dose Valganciclovir is Effective for CMV Prevention without Excess Breakthrough or Resistance in Kidney Transplantation
*Purpose: Reduced dose valganciclovir (VGC) (450 mg daily) may be a useful alternative to full dose VGC for cytomegalovirus (CMV) prophylaxis due to drug cost…2020 American Transplant Congress
Efficacy Of CMV Prophylaxis In Liver Transplant Recipients
Intermountain Medical Center, Murray, UT
*Purpose: Human cytomegalovirus (CMV) is a ubiquitous beta herpesvirus present in the human population at rates between 30% and 90%. It can be transmitted via…2020 American Transplant Congress
Conversion to Belatacept (BLT)- from Calcineurin Inhibitor (CNI)-Based Immunosuppression During the First Year Post-Transplant (<1yr Tx) Increases Risk for CMV Infection Through Inhibition of Anti-CMV Humoral Immunity
Cedars-Sinai Medical Center, Los Angeles, CA
*Purpose: We have shown a higer CMV infection rate in kidney Tx patients (KTx Pts) who were converted to BLT 1yr post-Tx. Viral infections are…2020 American Transplant Congress
Use of Letermovir for Cytomegalovirus Management in Thoracic Organ Transplantation
Duke University Medical Center, Durham, NC
*Purpose: Cytomegalovirus (CMV) commonly affects thoracic solid organ transplant (SOT) recipients, and standard antiviral therapies are limited by myelosuppression, renal dysfunction, and emergence of resistance.…2020 American Transplant Congress
A Comprehensive Evaluation of Risk Factors for Pneumocystis Jiroveci Pneumonia in Solid Organ Transplant Recipients: A Systematic Review and Meta-Analysis
*Purpose: Pneumocytis jiroveci pneumonia (PJP) is an important opportunistic fungal infection in solid organ transplant (SOT) recipients that carries a significant morbidity and mortality. Several…2020 American Transplant Congress
Single Center Experience of Valganciclovir and Adjunctive CMV IVIG for the Treatment of CMV Infection in Lung Transplant Recipients
*Purpose: Cytomegalovirus(CMV) infection happens commonly and causes significant morbidity in lung transplant (LTx) recipients. The use of CMV hyperimmune globulin (CMVIg) as an adjunctive treatment…2020 American Transplant Congress
Letermovir Treatment for Established Cytomegalovirus Infection in Transplant Recipients
*Purpose: The purpose of the study was to describe the patterns of use and clinical/virologic outcomes of letermovir treatment for established CMV infection in transplant…
American Transplant Congress abstracts